Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05835219 · ClinicalTrials.gov registry record
REBYOTA™ Prospective Registry
A clinical trial, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- 145
- Enrollment target
NCT05835219 is a clinical trial that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 145 participants.
The verdict
NCT05835219 has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- 145 participants
- Enrollment target
Study Summary
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (primary and recurrent: severity, treatment), CDI-related symptoms, treatments, medical procedures, Adverse Events(AEs), and healthcare resource utilization (i.e., hospitalizations and re-admissions) will be collected through 6 months of follow-up from the date of REBYOTA™ administration.
Interventions
- DRUG REBYOTA™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2023-06-19 |
| Est. Completion | 2025-08-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05835219
The ClinicalTrials.gov registry entry for NCT05835219 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REBYOTA™ is the first listed.
NCT05835219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05835219 about?
NCT05835219 is a clinical study titled "REBYOTA™ Prospective Registry". This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and...
What is the current status of trial NCT05835219?
This trial is currently completed. The enrollment target is 145 participants. The study started on 2023-06-19. Estimated completion is 2025-08-29.
What interventions are being tested in trial NCT05835219?
The interventions under investigation include: REBYOTA™ (DRUG).
Who is sponsoring clinical trial NCT05835219?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.